We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.
Management’s guidance emphasized continued Atruvio-driven growth and improving financial durability: Q1 total revenue was $194.5M (vs. $116.6M YoY) led by Atruvio U.S. net product revenue of $180.6M (24% q/q, +392% YoY), a $143.9M Atruvio lift that contributed to a $77.9M revenue increase overall; royalty revenue rose to $9.5M while license/services fell to $0.4M (prior-year $79.7M). They reported total operating expenses of $290.5M (SG&A $163.9M, +$57.5M; R&D $126.6M, +$15.2M), a $106M operating loss (but losses have narrowed >50% over five quarters), and $940.2M in cash and marketable securities (up from $587.5M), with guidance that losses should flatten over the next two quarters and the company expects to reach P&L breakeven and then sustainable cash-flow positivity by year‑end; the board also authorized a $500M share‑repurchase program to start immediately. Operational and pipeline metrics cited to support commercial outlook included >6,100 new patient starts in the ATTR class this quarter, a projected $4B peak for Atruvio, an IP runway of at least six years, real‑world signals such as a 43% reduction in diuretic intensification vs. tafamidis and Phase III OLE month‑54 mortality reductions (all‑cause −45%, CV −49%, p<0.0001), ~500 genetically confirmed LGMD2I U.S. patients, ~2,000 ADH1 patients identifiable via claims, achondroplasia unaided awareness >40%, and infigratinib’s 2.1 cm annualized height‑velocity benefit.
Atruvio U.S. net product revenue of $180.6 million in Q1 2026, representing 24% quarter‑over‑quarter growth and 392% year‑over‑year growth; company describes brand as becoming a 2026 blockbuster with growing frontline share and >6,100 total new patient starts in the category this quarter.
Total revenues of $194.5 million vs. $116.6 million in Q1 2025 (+$77.9M); royalty revenue increased to $9.5 million (up $9.3M), driven by acoramidis sales in Europe and Japan.
Independent RWE demonstrated acoramidis outcome improvements vs tafamidis (including a reported 43% reduction in diuretic intensification in a medRxiv study); Phase III open‑label extension showed sustained benefit at month 54 with a 45% reduction in all‑cause mortality and 49% reduction in cardiovascular mortality (both p<0.0001 vs placebo).
Cash, cash equivalents and marketable securities of $940.2 million (vs $587.5M at prior year‑end); Board authorized a $500 million share repurchase program to capture intrinsic value and concentrate ownership.
Three near‑term commercial opportunities (LGMD2I, ADH1/encaleret, achondroplasia/infigratinib) with active launch preparation: LGMD2I NDA submitted ~155 days after top‑line; ADH1 claims analytics identified nearly 2,000 U.S. patients; achondroplasia PROPEL‑3 positive with early commercial research showing >40% unaided awareness among prescribers.
PROPEL results: infigratinib showed a 2.1 cm annualized height velocity change (largest across Phase III programs) and the only statistically significant improvement in body proportionality in 3–8 year olds; company cites market research projecting >65% potential market share and expects oral option to expand market several‑fold over time.
Loss from operations of $106 million in Q1, but management reports operating loss has narrowed by >50% over the last five quarters (improvement trend post‑Atruvio launch) and expects transition toward P&L breakeven and sustainable cash flow positivity later in the year.
Investments in commercial and medical leadership, patient identification (ICD‑10 analytics, genetic testing, family tracing), and field reimbursement capabilities to support day‑one launches and ongoing growth across multiple rare disease franchises.
Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. And if you would like to withdraw your question, press 1 again. Thank you. Before we begin, I would like to remind everyone that today's call may contain forward looking statements within the meaning of the federal securities law, including but not limited to statements about BridgeBio Pharma, Inc.'s future operating and financial performance, business plans and prospects, and strategy. These statements are based on current expectations and assumptions that are subject to risk and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio Pharma, Inc.'s periodic reports and SEC filings. All statements made here are based on information available to BridgeBio Pharma, Inc. as of today, and the company undertakes no obligation to update any forward looking statements made during this call except as required by law. With that completed, BridgeBio Pharma, Inc., you may begin your conference.
Good afternoon, everyone, and thank you for joining BridgeBio Pharma, Inc.'s first quarter 2026 earnings call. I am Chinmay Shukla, Senior Vice President, Strategic Finance. With me are Neil Kumar, our CEO, Matthew Outten, our Chief Commercial Officer, and Thomas Trimarchi, our President and Chie...